Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Post by richardtraderon Aug 11, 2016 4:34pm
186 Views
Post# 25132802

Nasdaq

Nasdaq

 By NASDAQ.com News


Read more: https://www.nasdaq.com/article/Thu,%2011%20Aug%202016%2016:00:03%20-0400#ixzz4H3eItmW

Concordia International Corp.) is reporting for the quarter ending June 30, 2016. The drug company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.48. This value represents a 54.17% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 51 days. Zacks Investment Research reports that the 2016 Price to Earnings ratio for CXRX is 2.60 vs. an industry ratio of -4.00, implying that they will have a higher earnings growth than their competitors in the same industry. 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities